- Home
- CYRX vs RCKT Comparison
CYRX vs RCKT Comparison
Compare CYRX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | RCKT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | 1100 | 202 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 534.2M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | CYRX | RCKT |
|---|---|---|
| Price | $9.69 | $3.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $12.94 | ★ $29.73 |
| AVG Volume (30 Days) | 396.2K | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | $69.83 |
| P/E Ratio | $6.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.21 | $2.19 |
| 52 Week High | $11.45 | $8.26 |
Technical Indicators
Market Signals| Indicator | CYRX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 68.01 | 43.57 |
| Support Level | $9.18 | $2.99 |
| Resistance Level | $10.23 | $4.08 |
| Average True Range (ATR) | 0.43 | 0.32 |
| MACD | 0.19 | -0.05 |
| Stochastic Oscillator | 90.87 | 17.83 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.